Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial)
ConclusionAmenorrhea at 18 months was less likely in recipients of adjuvant T-DM1 than TH. Future studies are needed to understand how T-DM1 impacts risk of infertility and permanent menopause, and to assess amenorrhea rates when T-DM1 is administered after standard HER2-directed chemotherapy regimens.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
More News: Amenorrhea | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | HER2 | Herceptin | Hormones | Hysterectomy | Infertility | Men | Menopause | Ovarian Cancer | Ovaries | Reproduction Medicine | Study | Toxicology